X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GLENMARK PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GLENMARK PHARMA CIPLA/
GLENMARK PHARMA
 
P/E (TTM) x 44.6 12.2 365.3% View Chart
P/BV x 3.8 3.2 118.5% View Chart
Dividend Yield % 0.3 0.4 89.7%  

Financials

 CIPLA   GLENMARK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
GLENMARK PHARMA
Mar-17
CIPLA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs622993 62.6%   
Low Rs458729 62.8%   
Sales per share (Unadj.) Rs181.9325.5 55.9%  
Earnings per share (Unadj.) Rs12.939.3 32.8%  
Cash flow per share (Unadj.) Rs29.348.7 60.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.2 159.4%  
Book value per share (Unadj.) Rs155.7159.2 97.8%  
Shares outstanding (eoy) m804.51282.17 285.1%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.6 112.3%   
Avg P/E ratio x42.021.9 191.5%  
P/CF ratio (eoy) x18.417.7 104.1%  
Price / Book Value ratio x3.55.4 64.1%  
Dividend payout %15.55.1 305.3%   
Avg Mkt Cap Rs m434,516242,991 178.8%   
No. of employees `00023.013.0 177.7%   
Total wages/salary Rs m26,33816,408 160.5%   
Avg. sales/employee Rs Th6,349.17,083.9 89.6%   
Avg. wages/employee Rs Th1,143.01,265.4 90.3%   
Avg. net profit/employee Rs Th449.3855.1 52.6%   
INCOME DATA
Net Sales Rs m146,30291,857 159.3%  
Other income Rs m2,287374 612.0%   
Total revenues Rs m148,58992,230 161.1%   
Gross profit Rs m24,75820,367 121.6%  
Depreciation Rs m13,2292,644 500.4%   
Interest Rs m1,5942,373 67.2%   
Profit before tax Rs m12,22215,724 77.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,7983,827 47.0%   
Profit after tax Rs m10,35411,088 93.4%  
Gross profit margin %16.922.2 76.3%  
Effective tax rate %14.724.3 60.4%   
Net profit margin %7.112.1 58.6%  
BALANCE SHEET DATA
Current assets Rs m87,37068,746 127.1%   
Current liabilities Rs m33,08127,027 122.4%   
Net working cap to sales %37.145.4 81.7%  
Current ratio x2.62.5 103.8%  
Inventory Days Days8785 102.3%  
Debtors Days Days6296 65.2%  
Net fixed assets Rs m111,56724,132 462.3%   
Share capital Rs m1,609282 570.2%   
"Free" reserves Rs m123,64544,643 277.0%   
Net worth Rs m125,25444,925 278.8%   
Long term debt Rs m36,45445,363 80.4%   
Total assets Rs m209,532117,639 178.1%  
Interest coverage x8.77.6 113.7%   
Debt to equity ratio x0.31.0 28.8%  
Sales to assets ratio x0.70.8 89.4%   
Return on assets %5.711.4 49.8%  
Return on equity %8.324.7 33.5%  
Return on capital %8.519.1 44.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06656,152 90.9%   
Fx outflow Rs m17,6788,084 218.7%   
Net fx Rs m33,38848,068 69.5%   
CASH FLOW
From Operations Rs m23,8246,574 362.4%  
From Investments Rs m-13,127-7,124 184.3%  
From Financial Activity Rs m-13,2395,432 -243.7%  
Net Cashflow Rs m-2,4781,992 -124.4%  

Share Holding

Indian Promoters % 16.0 48.3 33.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 6.9 176.8%  
FIIs % 23.7 34.4 68.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 56,727 284.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 23, 2018 (Close)

TRACK CIPLA

CIPLA - TTK HEALTHCARE COMPARISON

COMPARE CIPLA WITH

MARKET STATS